Dr Gabe Musso, Chief Scientific Officer, Lunai Bioworks, will be speaking at the DDW track Creating Cures: The role of lab automation in successful drug discovery at SLAS2026. Dr Gabe Musso, Chief Scientific Officer, Lunai Bioworks He will present: De-Risking the Translation Gap: Coupling AI with… Read More
This webinar, sponsored by Benchling, provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually… Read More
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have jointly identified 10 principles for good artificial intelligence (AI) practice in the medicines lifecycle. The principles give broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research… Read More
Mike Ouren, Director of Business Development, Brooks Automation, will be speaking at the DDW track Creating Cures: The role of lab automation in successful drug discovery at SLAS2026. Mike Ouren, Director of Business Development, Brooks Automation He will offer insight into the Top Five challenges to… Read More
This webinar, sponsored by Benchling, provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually… Read More
NVIDIA has announced a major expansion of NVIDIA BioNeMo, its open development platform for AI-driven biology and drug discovery, at the JP Morgan Healthcare Conference. The platform has expanded to include: New NVIDIA Clara open models, the RNAPro model for RNA structure prediction and the ReaSyn v2 model BioNeMo Recipes… Read More
This webinar, sponsored by Benchling, provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually… Read More
This webinar, sponsored by Benchling, provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually… Read More
Ben Sidders, Chief Scientific Officer at Biorelate, explores how emerging AI-driven technologies are revealing hidden cause-and-effect relationships within existing biomedical data. Nearly 30% of FDA-approved drugs eventually gain additional indications beyond their original approval and are some of the highest-value and most challenging assessments in drug development. Indication expansion is… Read More
This webinar, sponsored by Benchling, provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually… Read More
Insilico Medicine listed on the Hong Kong Stock Exchange at the end of 2025, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX. This initial public offering (IPO) raised a total of HKD 2.277 billion ($292 million), achieving the… Read More
Talus Bioscience and PRISM BioLab have agreed to join forces with the aim of accelerating the discovery and development of novel small-molecule modulators of transcription factor (TF) and protein-protein interaction (PPI) targets. The collaboration combines Talus Bio’s regulome profiling and AI-guided drug discovery platform with PRISM’s chemistry platform. “This collaboration… Read More
Chai Discovery has announced a $130 million Series B financing round co-led by Oak HC/FT and General Catalyst. The news follows Chai’s most recent announcement, where the company showed its latest models can now design molecules with important “developability” properties and tackle “hard-to-drug” targets that have historically been challenging for… Read More
AI has reached a turning point in biotech. Real-world scientific agents are beginning to automate the repetitive tasks that slow down research, and transform how we think about extracting insights from scientific data. In this webinar, hosted by DDW and supported by Benchling, we will learn how organisations can… Read More
A collaboration between ARC Innovation at Sheba Medical Center, Icahn School of Medicine at Mount Sinai and NVIDIA will use the power of artificial intelligence (AI) in a bid to better understand the unexplored regions of the genome. The three-year collaboration will see the groups work together to create an… Read More
AI has reached a turning point in biotech. Real-world scientific agents are beginning to automate the repetitive tasks that slow down research, and transform how we think about extracting insights from scientific data. In this webinar on… Read More
